INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

Core Viewpoint - Iovance Biotherapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and operational issues [1][2]. Financial Performance - For Q1 2025, Iovance reported a loss of $0.36 per share on revenue of $49 million, missing consensus estimates of a loss of $0.24 per share on revenue of $82 million [2]. - The company's operational bottleneck, caused by a 50% reduction in capacity at the Iovance Cell Therapy Center for a month in December 2024, limited the number of Amtagvi infusions available in Q1 [2]. Stock Market Reaction - Following the announcement of the financial results and operational issues, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [3].